As of 2024-10-07, the Intrinsic Value of Halozyme Therapeutics Inc (HALO) is
58.64 USD. This HALO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 59.18 USD, the upside of Halozyme Therapeutics Inc is
-0.90%.
The range of the Intrinsic Value is 36.07 - 129.95 USD
58.64 USD
Intrinsic Value
HALO Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
36.07 - 129.95 |
58.64 |
-0.9% |
| DCF (Growth 10y) |
57.20 - 190.86 |
89.55 |
51.3% |
| DCF (EBITDA 5y) |
71.78 - 114.95 |
92.33 |
56.0% |
| DCF (EBITDA 10y) |
91.28 - 160.55 |
122.30 |
106.7% |
| Fair Value |
66.56 - 66.56 |
66.56 |
12.46% |
| P/E |
66.30 - 130.98 |
95.95 |
62.1% |
| EV/EBITDA |
58.97 - 99.12 |
74.65 |
26.1% |
| EPV |
13.31 - 26.03 |
19.67 |
-66.8% |
| DDM - Stable |
19.94 - 76.15 |
48.05 |
-18.8% |
| DDM - Multi |
34.49 - 106.98 |
52.72 |
-10.9% |
HALO Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
7,496.92 |
| Beta |
1.22 |
| Outstanding shares (mil) |
126.68 |
| Enterprise Value (mil) |
8,811.57 |
| Market risk premium |
4.60% |
| Cost of Equity |
9.25% |
| Cost of Debt |
4.25% |
| WACC |
8.30% |